Supplemental Online Content

Clift AK, Ranger TA, Patone M, et al. Neuropsychiatric ramifications of severe COVID-19 and other severe acute respiratory infections. *JAMA Psychiatry.* Published online May 11, 2022. doi:10.1001/jamapsychiatry.2022.1067

**eMethods.** Deviations From Study Protocol

**eFigure.** Flowchart Summarising Study Cohort Derivation

**eTable 1.** Incidence Rates for Neuropsychiatric Sequelae in Historic and Contemporary Cohorts

**eTable 2.** Unadjusted, Age/Sex-Adjusted, and Maximally Adjusted Hazard Ratios for Primary Analysis

**eTable 3.** Sensitivity Analysis Results (Calendar and Follow-up Time)

**eTable 4.** Sensitivity Analysis Results (Restricting to Those With COVID-19 as Primary Reason for Admission on Hospitalization Record)

This supplemental material has been provided by the authors to give readers additional information about their work.
eMethods. Deviations from the protocol

In the primary analysis cohort, we added a comparison of post-COVID-19 and post-SARI incidence to that in the general population, whereas only a direct comparison between the two diseases was initially planned. We believe the new analysis is more informative and relevant, but also present the results obtained using the initial analysis plan in the main paper. Additional outcomes were explored beyond those listed in the cohort based on clinical relevance, these were: Bipolar disorder (ICD-10 codes F30-31 and corresponding Read codes), Depression (F06.3, F32-F33, F34.1, F41.2, F44.8, F92.0 and corresponding Read codes) and Schizophrenia (F06.2, F20, F23.0-F23.2 and corresponding Read codes). Bipolar disorder is included in the broader category of mood disorders, schizophrenia is included in the category psychotic disorders and anti-depressant use is included in the hypnotics and anxiolytics category, nevertheless they were highlighted for their particular clinical importance and we have been careful not to over-interpret the results beyond those of the broader categories. We did not have sufficient event counts for incident schizophrenia diagnoses for a formal analysis.

A frailty term was initially proposed for the proportional hazards models to account for the clustered nature of the primary care data, but the use of Royston-Parmar models (Stata package stpm2) precluded this. Instead, we calculated robust standard errors clustered by general practice to account for clustering therein. We also proposed to combine the pre-pandemic and contemporary cohorts as part of the sequelae analysis in order to conduct competing risk analysis and calculate propensity scores of the likelihood of an event. The intention behind combining these cohorts was to account for potentially low event counts, but this proved unnecessary. Furthermore, combining them would have necessitated exclusion of patients who experienced an event in both cohorts, and may have been problematic due to changes in baseline characteristics. We did not feel a reasonable assumption could be made to exclude one event or the other. Given the sufficiency of event numbers and the lack of an acceptable assumption we abandoned this sub-analysis.

The sensitivity analysis assigning a random ‘start date’ to members of the reference group that were not admitted to hospital was not initially planned in the protocol. The sensitivity analysis excluding those individuals in the COVID-19-hospitalization survivor set that did not have COVID-19 recorded as the primary reason for admission (e.g. those admitted with a positive test within the preceding 14 days, but not as primary reason for admission) was in response to peer review. The post-hoc analytic comparisons with acute myocardial infarction patients reaching hospital discharge were also added in response to peer review.
**eFigure.** Flowchart demonstrating derivation of the final study cohort. SARI = severe acute respiratory infection.

Start cohort

Adults registered with general practices contributing to QResearch on 24th January 2020 onwards

$n = 8,388,956$

(20,882 SARI hospitalization survivors, 38,284 COVID-19 hospitalization survivors)

Final study cohort

$n = 8,380,190$

16,679 SARI hospitalization survivors, 32,525 COVID-19 hospitalization survivors

4,705 COVID hospitalisation survivors left QResearch database before discharge date

3,096 SARI hospitalisation survivors left QResearch database before discharge date

965 survived both SARI and COVID hospitalizations during study period
|                             | SARI hospitalization survivors n=212,935 | SARI hospitalization survivors n=16,679 | COVID hospitalization survivors n=32,525 | Reference population n=8,330,986 |
|-----------------------------|------------------------------------------|------------------------------------------|------------------------------------------|---------------------------------|
| Crude incidence rate (per 100,000) | Anxiety 414.56 (386.92 to 444.17) | 1807.79 (1605.19 to 2243.73) | 1975.36 (1706.18 to 2287.01) | 992.95 (983.75 to 1000.20) |
|                             | Dementia 1555.48 (1499.86 to 1613.17) | 2023.76 (1729.85 to 2367.06) | 1310.28 (1100.36 to 1560.26) | 181.90 (178.95 to 184.89) |
|                             | Mood disorder 370.50 (344.35 to 398.64) | 478.16 (343.31 to 665.96) | 357.23 (253.97 to 502.49) | 141.55 (138.89 to 144.26) |
|                             | Psychosis 39.82 (31.93 to 49.64) | 110.83 (57.67 to 213.01) | 100.18 (53.90 to 186.19) | 23.99 (22.94 to 25.09) |
|                             | Bipolar 19.62 (14.34 to 26.86) | 147.46 (83.74 to 259.65) | 119.85 (68.06 to 211.03) | 52.08 (50.52 to 53.69) |
|                             | Depression 160.83 (142.99 to 180.90) | 278.18 (177.44 to 436.12) | 138.52 (78.67 to 243.91) | 62.60 (60.80 to 64.45) |
|                             | Antidepressant use 1267.33 (1199.82 to 1338.64) | 7592.52 (6728.20 to 8567.88) | 7639.98 (6907.34 to 8450.32) | 2213.37 (2200.64 to 2226.18) |
|                             | Hypnotic/anxiolytic use 1098.12 (1042.21 to 1157.02) | 6274.21 (5596.49 to 7033.99) | 5665.60 (5111.02 to 6280.35) | 1034.13 (1026.16 to 1042.17) |
|                             | Anti-psychotic use 1128.54 (1081.15 to 1178.01) | 7082.70 (6504.15 to 7712.72) | 4378.99 (3975.93 to 4822.93) | 356.51 (352.34 to 360.72) |
| Age- and sex-standardized incidence rates (per 100,000) | Anxiety F 533.74 (489.45 to 578.04) | 2150.85 (1677.04 to 2624.67) | 3954.52 (3264.28 to 4644.76) | 1395.57 (1383.30 to 1407.84) |
|                             | M 272.56 (238.44 to 306.68) | 1649.76 (1229.63 to 2069.9) | 1424.81 (1044.61 to 1807.06) | 614.37 (606.55 to 622.20) |
|                             | Dementia F 1666.80 (1591.61 to 1744.40) | 2156.33 (1712.00 to 2600.66) | 1892.63 (1447.17 to 2338.09) | 187.94 (183.96 to 191.92) |
|                             | M 1355.19 (1275.47 to 1434.92) | 1849.85 (1414.60 to 2285.11) | 1603.49 (1205.01 to 2001.97) | 170.08 (166.43 to 175.10) |
|                             | Mood disorder F 398.24 (359.58 to 436.89) | 556.95 (312.56 to 801.34) | 489.52 (245.16 to 733.89) | 171.08 (166.84 to 175.31) |
|                             | M 338.80 (300.71 to 376.89) | 413.85 (204.29 to 623.41) | 447.02 (230.55 to 663.48) | 113.40 (110.04 to 116.77) |
|                             | Psychosis F 38.18 (26.30 to 50.06) | 125.29 (15.00 to 235.58) | 104.90 (0.18 to 209.61) | 20.67 (19.26 to 22.08) |
|                             | M 41.89 (28.69 to 55.08) | 105.95 (2.12 to 209.79) | 140.59 (7.27 to 253.47) | 26.90 (25.30 to 28.50) |
|                             | Bipolar F 26.63 (16.74 to 36.51) | 186.67 (57.17 to 316.18) | 203.13 (59.38 to 346.88) | 64.59 (62.07 to 67.10) |
|                             | M 12.56 (5.09 to 20.02) | 104.07 (1.76 to 206.38) | 114.56 (0.00 to 230.09) | 40.04 (38.09 to 42.00) |
|                             | Depression F 161.72 (135.36 to 188.07) | 312.85 (191.34 to 506.36) | 169.12 (17.30 to 320.95) | 72.03 (69.21 to 74.86) |
|                             | M 159.75 (132.12 to 187.38) | 259.84 (90.07 to 429.60) | 179.32 (46.07 to 312.57) | 53.79 (51.44 to 56.14) |
|                             | Antidepressant use F 1469.47 (1359.37 to 1579.56) | 7780.32 (6409.21 to 9151.44) | 9749.25 (8175.49 to 11323.01) | 2787.35 (2766.09 to 2808.61) |
|                             | M 1077.03 (989.61 to 1164.45) | 7018.84 (5908.32 to 8129.37) | 9043.33 (7919.92 to 10166.73) | 1719.93 (1705.10 to 1734.76) |
|                             | Hypnotic/anxiolytic use F 1177.07 (1093.49 to 1260.65) | 6194.26 (5182.31 to 7206.21) | 6946.83 (5824.58 to 8069.07) | 1234.31 (1221.69 to 1246.93) |
|                             | M 994.59 (916.77 to 1072.41) | 5887.05 (4977.52 to 6796.59) | 7262.96 (6324.08 to 8201.84) | 848.07 (838.09 to 858.04) |
|                             | Anti-psychotic use F 1141.54 (1076.71 to 1206.37) | 6615.04 (5844.21 to 7385.88) | 5739.73 (4984.59 to 6494.88) | 365.53 (359.80 to 371.25) |
|                             | M 1089.97 (1017.97 to 1161.97) | 6986.22 (6179.90 to 7792.54) | 5363.46 (4674.54 to 6052.38) | 344.03 (337.90 to 350.17) |
eTable 1. Crude and age-standardized incidence rates (with 95% confidence intervals) per 100,000 person-years for neuropsychiatric sequelae following surviving a hospital admission for severe acute respiratory infections or COVID-19. Follow-up was limited to one year for comparability. Direct standardization was used. F = female sex; M = male
| Endpoint of interest | Unadjusted hazard ratio (95% confidence interval) | Age and sex-adjusted hazard ratio (95% confidence interval) | Maximally adjusted (primary analysis; 95% confidence interval) |
|----------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|
| Anxiety              |                                                  |                                                  |                                                  |
| SARI                 | 1.88 (1.59 to 2.21)                              | 2.54 (2.12 to 2.96)                              | 1.86 (1.56 to 2.21)                              |
| COVID-19             | 1.92 (1.65 to 2.23)                              | 2.49 (2.12 to 2.86)                              | 2.36 (2.03 to 2.74)                              |
| Dementia             |                                                  |                                                  |                                                  |
| SARI                 | 11.06 (9.43 to 1.96)                             | 2.90 (2.43 to 3.36)                              | 2.55 (2.17 to 3.00)                              |
| COVID-19             | 6.99 (5.88 to 8.32)                              | 2.92 (2.42 to 3.42)                              | 2.63 (2.21 to 3.14)                              |
| Psychotic disorder   |                                                  |                                                  |                                                  |
| SARI                 | 4.49 (2.34 to 8.60)                              | 4.99 (1.74 to 8.24)                              | 3.63 (1.88 to 7.00)                              |
| COVID-19             | 3.97 (2.14 to 7.37)                              | 4.35 (1.66 to 7.03)                              | 3.05 (1.58 to 5.90)                              |
| Depression           |                                                  |                                                  |                                                  |
| SARI                 | 4.40 (2.90 to 6.70)                              | 5.22 (3.02 to 7.42)                              | 3.46 (2.21 to 5.40)                              |
| COVID-19             | 2.15 (1.16 to 3.99)                              | 2.56 (0.99 to 4.13)                              | 1.95 (1.05 to 3.65)                              |
| Bipolar affective disorder |                                            |                                                  |                                                  |
| SARI                 | 2.76 (1.57 to 4.84)                              | 3.69 (1.61 to 5.77)                              | 2.26 (1.25 to 4.08)                              |
| COVID-19             | 2.17 (1.24 to 3.82)                              | 2.83 (1.23 to 4.43)                              | 2.26 (1.25 to 4.07)                              |
| Antidepressant prescription |                                           |                                                  |                                                  |
| SARI                 | 3.44 (3.05 to 3.88)                              | 3.30 (2.90 to 3.70)                              | 2.55 (2.24 to 2.90)                              |
| COVID-19             | 3.44 (3.10 to 3.81)                              | 3.60 (3.23 to 3.97)                              | 3.24 (2.91 to 3.61)                              |
| Hypnotic/anxiolytic prescription |                              |                                                  |                                                  |
| SARI                 | 6.01 (5.35 to 6.75)                              | 4.45 (3.93 to 4.87)                              | 3.10 (2.74 to 3.51)                              |
| COVID-19             | 5.33 (4.78 to 5.95)                              | 4.56 (4.07 to 5.05)                              | 3.79 (3.38 to 4.25)                              |
| Antipsychotic prescription |                                         |                                                  |                                                  |
| SARI                 | 19.58 (17.95 to 21.37)                           | 6.52 (5.92 to 7.12)                              | 4.64 (4.20 to 5.12)                              |
| COVID-19             | 11.91 (10.76 to 13.18)                           | 6.18 (5.55 to 6.81)                              | 4.78 (4.28 to 5.33)                              |

**eTable 2.** Comparison of unadjusted, age and sex-adjusted, and maximally adjusted hazard ratios (with 95% confidence intervals) from the primary analysis – neuropsychiatric sequelae after discharge from SARI- or COVID-19-related hospitalization, with the remaining population as the reference group.
| Endpoint of interest          | Primary analysis | Sensitivity analysis |
|-----------------------------|------------------|---------------------|
| Anxiety                     |                  |                     |
| SARI                        | 1.86 (1.56 to 2.21) | 1.99 (1.68 to 2.35) |
| COVID-19                    | 2.36 (2.03 to 2.74) | 2.47 (2.13 to 2.87) |
| Dementia                    |                  |                     |
| SARI                        | 2.55 (2.17 to 3.00) | 2.51 (2.13 to 2.96) |
| COVID-19                    | 2.63 (2.21 to 3.14) | 2.63 (2.20 to 3.14) |
| Psychotic disorder          |                  |                     |
| SARI                        | 3.63 (1.88 to 7.00) | 3.47 (1.79 to 6.73) |
| COVID-19                    | 3.05 (1.58 to 5.90) | 3.35 (1.77 to 6.34) |
| Depression                  |                  |                     |
| SARI                        | 3.46 (2.21 to 5.40) | 3.50 (2.28 to 5.37) |
| COVID-19                    | 1.95 (1.05 to 3.65) | 2.17 (1.17 to 4.02) |
| Bipolar affective disorder  |                  |                     |
| SARI                        | 2.26 (1.25 to 4.08) | 2.45 (1.39 to 4.34) |
| COVID-19                    | 2.26 (1.25 to 4.07) | 2.59 (1.47 to 4.56) |
| Antidepressant prescription |                  |                     |
| SARI                        | 2.55 (2.24 to 2.90) | 2.53 (2.45 to 2.86) |
| COVID-19                    | 3.24 (2.91 to 3.61) | 3.21 (2.89 to 3.57) |
| Hypnotic/anxiolytic prescription |              |                     |
| SARI                        | 3.10 (2.74 to 3.51) | 3.32 (2.94 to 3.75) |
| COVID-19                    | 3.79 (3.38 to 4.25) | 4.00 (3.59 to 4.47) |
| Antipsychotic prescription  |                  |                     |
| SARI                        | 4.64 (4.20 to 5.12) | 4.80 (4.36 to 5.28) |
| COVID-19                    | 4.78 (4.28 to 5.33) | 4.95 (4.45 to 5.51) |

eTable 3 – Results from sensitivity analyses (maximally adjusted hazard ratios) wherein the reference population group were assigned a random cohort start date to account for varying timeframes in which follow-up was contributed and variation in baseline diagnostic rates during COVID-19 pandemic. Adjustment for calendar month was also performed. Comparison is made with the maximally adjusted hazard ratios from the primary analyses for reference. These analyses were conducted in the contemporary cohort.
| Endpoint of interest | Primary analysis | Sensitivity analysis |
|----------------------|------------------|---------------------|
| Anxiety              |                  |                     |
| SARI                 | 1.86 (1.56 to 2.21) | 1.91 (1.62 to 2.26) |
| COVID-19             | 2.36 (2.03 to 2.74) | 2.38 (1.97 to 2.87) |
| Dementia             |                  |                     |
| SARI                 | 2.55 (2.17 to 3.00) | 2.55 (1.18 to 2.99) |
| COVID-19             | 2.63 (2.21 to 3.14) | 2.45 (1.94 to 3.09) |
| Psychotic disorder   |                  |                     |
| SARI                 | 3.63 (1.88 to 7.00) | 3.38 (1.75 to 6.54) |
| COVID-19             | 3.05 (1.58 to 5.90) | 2.09 (0.78 to 5.58) |
| Depression           |                  |                     |
| SARI                 | 3.46 (2.21 to 5.40) | 3.53 (2.24 to 5.56) |
| COVID-19             | 1.95 (1.05 to 3.65) | 1.83 (0.82 to 4.07) |
| Bipolar affective disorder |          |                     |
| SARI                 | 2.26 (1.25 to 4.08) | 2.29 (1.30 to 4.04) |
| COVID-19             | 2.26 (1.25 to 4.07) | 2.25 (1.07 to 4.74) |
| Antidepressant prescription |          |                     |
| SARI                 | 2.55 (2.24 to 2.90) | 2.57 (2.28 to 2.90) |
| COVID-19             | 3.24 (2.91 to 3.61) | 2.70 (2.34 to 3.12) |
| Hypnotic/anxiolytic prescription |   |                     |
| SARI                 | 3.10 (2.74 to 3.51) | 3.17 (2.82 to 3.55) |
| COVID-19             | 3.79 (3.38 to 4.25) | 3.50 (3.05 to 4.03) |
| Antipsychotic prescription |          |                     |
| SARI                 | 4.64 (4.20 to 5.12) | 4.60 (4.22 to 5.02) |
| COVID-19             | 4.78 (4.28 to 5.33) | 4.45 (3.91 to 5.08) |

**eTable 4** – Maximally adjusted hazard ratios obtained from sensitivity analyses excluding COVID-19-related hospitalization survivors that did not have COVID-19 as the primary reason for admission to hospital (e.g. those that had a positive SARS-CoV-2 test within the preceding 14 days, but did not explicitly have COVID-19 as the primary reason for hospital admission). These analyses were conducted in the contemporary cohort.